Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5015366 | 0.99 | ALDH1A1 (0.53) | HTTALDH1A1MEN1KMT2ANPC1 | |
| Bromide SCHEMBL3846651 | 0.83 | HTT (0.48) | HTTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL5070441 | 0.82 | ALDH1A1 (0.48) | HTTALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL6766683 | 0.80 | ALDH1A1 (0.38) | HTTALDH1A1MEN1KMT2AMAPT | |
| Bromide SCHEMBL3850340 | 0.75 | MGAM (0.44) | HTTALDH1A1MEN1KMT2ANPC1 | |
| Bromide SCHEMBL3845607 | 0.74 | PTPN1 (0.42) | ALDH1A1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6535503 | 0.74 | CA12 (0.39) | HTTALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL6535178 | 0.73 | MGAM (0.45) | HTTALDH1A1MEN1KMT2ANPC1 | |
| Bromide SCHEMBL3845053 | 0.73 | ALDH1A1 (0.42) | ALDH1A1NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL6776693 | 0.72 | TRPV6 (0.41) | HTTALDH1A1MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020160992-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts | WAGLE DILIP R (US) | 2002-10-31 | — | — | US | claimed |
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-7384625-B2 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARINGTON PHARMACEUTICALS, LLC (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1128830-B1 | REVERSING ADVANCED GLYCOSYLATION CROSS-LINKS USING HETEROCYCLIC-SUBSTITUTED THIAZOLIUM SALTS | SYNVISTA THERAPEUTICS INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1353669-B1 | METHOD FOR TREATING GLAUCOMA | ALTEON INC (US) | 2007-08-15 | — | — | EP | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1305024-A4 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | FARRINGTON PHARMACEUTICALS, LLC | 2002-12-05 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| US-20020160992-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts | WAGLE DILIP R (US) | 2002-10-31 | — | — | US | disclosed |
| WO-2002056836-A2 | METHOD AND COMPOSITION FOR REJUVENATING HAIR, NAILS, TISSUES, CELLS AND ORGANS BY EX-VIVO OR IMMERSIVE TREATMENT | FARRINGTON PHARMACEUTICALS, LLC (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002053158-A1 | METHOD FOR TREATING GLAUCOMA IB | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
| WO-2002007725-A1 | METHOD FOR TREATING FIBROTIC DISEASES OR OTHER INDICATIONS IC | ALTEON, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| US-6319934-B1 | TREATING STIFFENING OF BLOOD VASCULATURE, ATHEROSCLEROSIS, RETINOPATHY, CATARACTS, PERIPHERAL NEUROPATHY OR OSTEOARTHRITIS IN AN ANIMAL | ALTEON, INC. | 2001-11-20 | — | — | US | disclosed |
| US-6121300-A | IN A TOPICAL COSMETIC AS SKIN ELASTICITY IMPROVER OR WRINKLE REDUCER; COMPOUNDS SUCH AS 3-(2-(3-PHENYL-5-ISOXAZOLYL)-2-OXOETHYL)-THIAZOLIUM; ADMINSISTERING TO TREAT CATARACTS, PROTEIN AGING AND DIABETES | SYNVISTA THERAPEUTICS, INC. | 2000-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020182165-A1 | Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment | COL1A1, KRT18, COL2A1 | HTT 51/4885ALDH1A1 825/4885MEN1 1166/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | HTT 2112/4885ALDH1A1 366/4885MEN1 1815/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | HTT 1948/4885ALDH1A1 204/4885MEN1 2481/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | HTT 2002/4885ALDH1A1 402/4885MEN1 3331/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | HTT 1312/4885ALDH1A1 261/4885MEN1 2134/4885 |
| US-20020160992-A1 | Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts | AGER, OGA, PTMS | HTT 134/4885ALDH1A1 1868/4885MEN1 4175/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | HTT 1758/4885ALDH1A1 448/4885MEN1 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.